High performance was exhibited by a biomarker panel combination including methylated SCD2 with methylated SFRP1 and/or SFRP2, with overall CRC sensitivities of 88.6–91.5% and specificities of 86.1–97.3%, alongside APL sensitivities of 60.0–89.2% [41, 58, 69, 79]. This evidence concerns the gene FASLG and colorectal carcinoma.